Core Viewpoint - Marubi Biological, known as the "first stock of eye cream" in A-shares, is preparing for a dual listing on the Hong Kong Stock Exchange while undergoing a power transition within the controlling family [2][3]. Group 1: Company Background and Control - Marubi Biological was founded by Sun Huaqing in 2002, focusing on eye care products and has maintained its position as the leading domestic eye care brand from 2021 to 2024 [1][19]. - The controlling shareholders, Sun Huaqing and Wang Xiaopu, hold a combined 80.8% of the company [3][10]. - The company underwent a significant dividend distribution before its IPO, benefiting the controlling family [4][30]. Group 2: IPO and Financial Adjustments - Marubi Biological submitted its IPO application to the Hong Kong Stock Exchange, aiming for an "A+H" dual listing [2]. - The company has faced challenges with its fundraising projects since its A-share listing, with all initial investment projects experiencing delays [5][7]. - Specific projects, such as the cosmetic smart manufacturing factory, have seen multiple delays and budget increases, indicating potential issues in project management [8][9]. Group 3: Financial Performance - Marubi Biological's revenue from 2022 to 2024 showed a compound annual growth rate (CAGR) of 31%, with net profits growing at a CAGR of 43% during the same period [22]. - The company reported a revenue of 24.5 billion yuan in the first nine months of 2025, a 25.5% year-on-year increase, but net profit growth slowed to only 2.86% [23]. - The gross profit margin has been steadily increasing, reaching 74.8% in 2025 [24]. Group 4: Marketing and Sales Strategy - The company has heavily invested in marketing, with total marketing expenses amounting to 4.464 billion yuan from 2022 to 2024, leading to a rising sales expense ratio [25]. - Online sales channels accounted for 87.6% of revenue in the first nine months of 2025, while offline channels have been declining [27]. Group 5: Regulatory Issues and Governance - Marubi Biological received a warning letter from the Guangdong Regulatory Bureau for financial accounting irregularities and improper management of raised funds [15][16]. - The company has committed to rectifying these issues and improving governance practices following the regulatory scrutiny [18].

Investment Rating - The report maintains a "Strong Buy" rating for the company [1][8]. Core Views - The company shows strong performance with a projected revenue growth of 33% and a net profit growth of 32% for 2024, continuing into Q1 2025 with revenue growth of 28% and net profit growth of 22% [1][2]. - The dual-brand strategy, featuring the main brand Marubi and the PL brand Lianhuo, is driving growth, with significant contributions from key products like the Marubi Eye Cream and the Golden Needle series [1][3]. - The company is expected to achieve net profits of 445 million, 549 million, and 643 million yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 30%, 23%, and 17% [1][8]. Financial Performance - In 2024, the company achieved a total revenue of 2.97 billion yuan, a year-on-year increase of 33.44%, and a net profit of 342 million yuan, up 31.69% [2][9]. - The main brand Marubi generated revenue of 2.06 billion yuan in 2024, growing by 31.69%, while the PL brand Lianhuo achieved 905 million yuan, a growth of 40.72% [3][9]. - The company's gross margin improved to 73.70% in 2024, up by 3.01 percentage points, attributed to product structure optimization and cost control [7][12]. Product and Channel Analysis - The company’s product categories showed strong performance, with eye care products generating 689 million yuan in revenue, a 60.78% increase, and skincare products reaching 1.13 billion yuan, up 21.60% [3][9]. - Online sales channels contributed significantly, with revenue of 2.54 billion yuan in 2024, reflecting a growth of 35.77%, while offline channels saw a 20.79% increase to 427 million yuan [3][9]. Future Outlook - The company is expected to continue its growth trajectory with a stable cash flow and a focus on product innovation, which is anticipated to contribute to incremental growth [8][9]. - The projected earnings per share (EPS) for 2025 is 1.11 yuan, with a price-to-earnings (PE) ratio of 39.3 [9][12].

Group 1: Consumption Policy and Market Trends - The government is expected to implement policies to promote childbirth, with significant subsidies announced in Hohhot, which may catalyze demand in the maternal and infant sector, benefiting companies like Aiyingshi and Haiziwang [6][8] - The retail sector is seeing a shift towards quality supermarkets, driven by consumer demand for better product quality, with companies like Yonghui Supermarket and Chongqing Department Store expected to expand [7][8] - The "AI + Consumption" initiative is being emphasized, with potential growth in sectors like AI-integrated eyewear and e-commerce, highlighting companies such as Mingyue Optical and Ruoyuchen [2] Group 2: Company-Specific Developments - Aimeike plans to acquire REGEN Biotech, which could enhance its market position and valuation, as the acquisition is expected to provide significant growth opportunities in both domestic and international markets [3] - The 3.8 promotion event on platforms like Tmall and Douyin showed strong performance, with brands like Juzi and Marubi exceeding expectations, indicating a robust recovery in the beauty sector [4][5] - Gaode Beauty reported a 9.3% increase in net sales for 2024, with significant growth in its aesthetic injection segment, particularly in China, where new products are expected to drive further growth [6]